A randomized, multiple dose, dose-escalation, double-blind, placebo-controlled phase I trial investigating the optimal safe dose of ALK ragweed tablet Ambrosia artemisiifolian in adult subjects with seasonal rhinoconjunctivitis caused by ragweed pollen allergy

Trial Profile

A randomized, multiple dose, dose-escalation, double-blind, placebo-controlled phase I trial investigating the optimal safe dose of ALK ragweed tablet Ambrosia artemisiifolian in adult subjects with seasonal rhinoconjunctivitis caused by ragweed pollen allergy

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Sep 2012

At a glance

  • Drugs Short ragweed pollen allergen extract (Ragwitek) (Primary)
  • Indications Allergic rhinoconjunctivitis; Ragweed pollen hypersensitivity
  • Focus Adverse reactions
  • Most Recent Events

    • 22 Mar 2011 Results presented at the 67th Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
    • 06 Jul 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top